A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Background Therapy
The objective of this study is to assess efficacy and safety of radium-223 dichloride in
subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone
receptor positive breast cancer with bone metastases treated with hormonal treatment
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society